{"gene":"RALA","run_date":"2026-04-28T19:45:45","timeline":{"discoveries":[{"year":1986,"finding":"RALA was identified as a new RAS-related GTPase with GTP-binding domains and a C-terminal cysteine for membrane anchoring, predicting it to be a membrane-localized GTP-binding protein.","method":"cDNA cloning from simian B-lymphocyte library using synthetic oligonucleotide probe; sequence analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — foundational cloning and structural characterization, highly cited","pmids":["3023062"],"is_preprint":false},{"year":1990,"finding":"Purified RalA protein binds and hydrolyzes GTP with low intrinsic GTPase activity (0.07 min-1 at 37°C) and slow GDP exchange; activating mutations (analogous to Ras Val12, Leu61) alter nucleotide exchange and GTPase activities, and NMR shows similar nucleotide-binding environment to p21Ras.","method":"In vitro biochemical assay with purified recombinant RalA; site-directed mutagenesis; NMR spectroscopy","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with mutagenesis and NMR structural validation","pmids":["2108160"],"is_preprint":false},{"year":1991,"finding":"A cytosolic GTPase-activating protein (Ral-GAP) specific for RalA was identified in brain and testis; it stimulates RalA GTPase activity but not Ras, Rho, or Rap GTPase activity, demonstrating substrate specificity.","method":"Biochemical fractionation; in vitro GTPase activity assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro assay with substrate specificity controls, single lab","pmids":["1903395"],"is_preprint":false},{"year":1995,"finding":"RalA interacts with phospholipase D (PLD); a Ral-specific N-terminal region is required for PLD association and PLD activation downstream of v-Src. Dominant-negative RalA inhibits v-Src- and v-Ras-induced PLD activity.","method":"Immunoprecipitation of PLD with immobilized RalA; dominant-negative overexpression; deletion mutagenesis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP and mutagenesis, published in Nature, highly cited","pmids":["7477381"],"is_preprint":false},{"year":1995,"finding":"RLIP76 (RalBP1) was identified as a RalA effector that binds activated (GTP-bound) RalA via its effector domain, and functions as a GAP for Rac1 and CDC42 but not RhoA, bridging Ral to Rho pathways.","method":"Yeast two-hybrid screening; biochemical pulldown with purified proteins; GAP activity assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — yeast two-hybrid confirmed by in vitro pulldown and enzymatic activity assay, highly cited","pmids":["7673236"],"is_preprint":false},{"year":1996,"finding":"Constitutively active RalA enhances Ras- and Raf-induced oncogenic transformation, while dominant-negative RalA suppresses transformation by RasH and Raf, placing Ral as a downstream effector in a Ras signaling pathway distinct from Raf.","method":"Genetic epistasis; dominant-negative and constitutively active mutant overexpression; transformation assay in mammalian cells","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — epistasis with gain- and loss-of-function mutants, highly cited","pmids":["8631302"],"is_preprint":false},{"year":1996,"finding":"Post-translational modification (prenylation) of both Ras and RalA is required for efficient RalGDS-mediated GDP/GTP exchange on RalA, for RalGDS membrane redistribution, and for RalA binding to its effector RalBP1.","method":"In vitro GDP/GTP exchange assay; cell fractionation; co-immunoprecipitation","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — multiple complementary biochemical methods, single lab","pmids":["8702675"],"is_preprint":false},{"year":1998,"finding":"RalA associates with an active PLD complex containing Arf proteins; the Ral-specific N-terminus is required for Arf association, and Arf is required for PLD activation in v-Src/v-Ras-transformed cells, demonstrating that RalA scaffolds a PLD-Arf complex.","method":"Pulldown with GST-RalA fusion; co-immunoprecipitation; Brefeldin A inhibitor study; dominant-negative Arf expression","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — reciprocal pulldown, pharmacological and genetic perturbation, multiple orthogonal methods","pmids":["9520417"],"is_preprint":false},{"year":1998,"finding":"RalA can be activated by a Ca2+-dependent, Ras-independent pathway triggered by LPA or EGF, involving phospholipase C activation; dominant-negative Ras did not block Ral-GTP loading.","method":"GTP-loading assay (Ral-GTP measurement) in Rat-2 fibroblasts; dominant-negative Ras; Ca2+ ionophore and PLC inhibitor","journal":"Current biology : CB","confidence":"Medium","confidence_rationale":"Tier 2 — genetic and pharmacological epistasis, single lab","pmids":["9663394"],"is_preprint":false},{"year":1999,"finding":"GTP-bound RalA specifically binds filamin (an actin filament-crosslinking protein) and induces actin-rich filopodia; dominant-negative RalA or the RalA-binding domain of filamin blocks Cdc42-induced filopod formation. RalA does not generate filopodia in filamin-deficient cells, placing RalA downstream of Cdc42 in filopod production using filamin.","method":"GTP-specific binding assay; dominant-negative mutant expression; filamin-deficient cell rescue by transfection; fluorescence microscopy","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — GTP-specific binding, genetic epistasis, loss-of-function rescue, highly cited","pmids":["10051605"],"is_preprint":false},{"year":1999,"finding":"Positions 36 and 37 in the effector domain of RalA determine specificity of RalA-RLIP76 interaction; mutating these residues converts Ral/Ras effector interaction specificity, despite no sequence homology between their binding domains.","method":"Sequence analysis; site-directed mutagenesis; binding assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 — mutagenesis with binding validation, single lab","pmids":["10364219"],"is_preprint":false},{"year":1999,"finding":"RalA is required for v-Src- and v-Ras-induced urokinase-type plasminogen activator (uPA) and MMP-2/MMP-9 overproduction, and for tumor formation in mice; dominant-negative RalA blocks these effects.","method":"Dominant-negative RalA expression; zymogram for MMP activity; subcutaneous tumor injection in mice","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with defined cellular and in vivo phenotypes","pmids":["10467419"],"is_preprint":false},{"year":2000,"finding":"EGF activates c-Src through a RalA-dependent mechanism (but not beta2-adrenergic receptor signaling), leading to phosphorylation of Stat3 and cortactin but not Shc or Erk; RalA thus specifies c-Src substrate selectivity downstream of EGF receptor.","method":"Constitutively active RalA overexpression; dominant-negative mutants; phosphorylation assays","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 — gain- and loss-of-function with phosphorylation readouts, single lab","pmids":["10675331"],"is_preprint":false},{"year":2000,"finding":"RalA and PLD1 cooperate with EGF receptor to transform 3Y1 rat fibroblasts; EGF-induced PLD activation requires both Ras and RalA, while Erk activation is RalA-independent. Overexpression of active RalA increases PLD activity and induces transformation.","method":"Dominant-negative RalA; PLD activity assay; transformation assay; co-immunoprecipitation","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 — loss- and gain-of-function with enzymatic and phenotypic readouts","pmids":["10611224"],"is_preprint":false},{"year":2000,"finding":"Dominant-negative RalA inhibits chemotactic migration of skeletal myoblasts in response to bFGF, HGF, and IGF-1; active Ral mutant or RalGDS stimulates motility; RalA-mediated motility requires binding to RalBP1 and PLD.","method":"Dominant-negative and constitutively active mutant overexpression; effector mutant analysis; chemotaxis assay","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 — effector mutant epistasis with phenotypic readout","pmids":["10848592"],"is_preprint":false},{"year":2001,"finding":"RalA localizes to Weibel-Palade bodies in endothelial cells and is activated (GTP-loaded) by thrombin stimulation in a calmodulin-dependent manner; constitutively active RalA drives Weibel-Palade body exocytosis.","method":"Subcellular fractionation; GTP-loading assay; calmodulin inhibitor (trifluoperazine); dominant-active and dominant-negative RalA expression; immunofluorescence","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 — localization linked to functional exocytosis, pharmacological and genetic perturbation","pmids":["11397694"],"is_preprint":false},{"year":2002,"finding":"The mammalian exocyst subunit Sec5 is a specific binding partner for GTP-bound RalA; inhibition of RalA-Sec5 interaction prevents filopod formation by TNF-α, IL-1, and active RalA/Cdc42, linking RalA-exocyst interaction to cytoskeletal remodeling.","method":"Yeast two-hybrid; co-immunoprecipitation; dominant-negative interference; filopod assay","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP, GTP-specificity demonstrated, genetic interference with functional readout, highly cited","pmids":["11744922"],"is_preprint":false},{"year":2002,"finding":"Pseudomonas ExoS ADP-ribosylates RalA at Arg52, inhibiting its ability to bind the RalBP1 effector; this identifies a post-translational modification that blocks RalA effector engagement.","method":"ADP-ribosylation assay; mass spectrometry for site identification; RalBP1-RBD binding assay in vitro and in cells","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 1 — in vitro enzymatic modification with site identification and functional binding assay","pmids":["12135390"],"is_preprint":false},{"year":2002,"finding":"Beta-arrestins bind Ral-GDS and sequester it in an inactive cytosolic complex; upon fMLP receptor stimulation, beta-arrestin/Ral-GDS complexes dissociate, Ral-GDS translocates to plasma membrane, and activates RalA in a Ras-independent manner to drive cytoskeletal reorganization.","method":"Yeast two-hybrid; co-immunoprecipitation from PMNs; subcellular fractionation; Ral-GTP assay","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 — yeast two-hybrid confirmed by co-IP from primary cells with functional readout","pmids":["12105416"],"is_preprint":false},{"year":2003,"finding":"Crystal structure of RalA-GppNHp bound to the Sec5 Ral-binding domain at 2.1 Å reveals Sec5 adopts an immunoglobulin-like beta-sandwich fold and contacts both switch regions of RalA; key residues Sec5-Thr11, Arg27 and RalA-Glu38 are required for complex formation.","method":"X-ray crystallography; isothermal titration calorimetry; mutagenesis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with mutagenesis and ITC validation","pmids":["12839989"],"is_preprint":false},{"year":2003,"finding":"RalBP1 interacts with HSF1 in a multiprotein complex with HSP90 and alpha-tubulin; constitutively active RalA enhances heat-inducible HSP70 expression while dominant-negative RalA suppresses it; upon heat shock, RalA-GTP binds RalBP1, releasing HSF1 for nuclear translocation.","method":"Yeast two-hybrid; co-immunoprecipitation; cotransfection with RalA mutants; reporter assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — yeast two-hybrid plus co-IP with functional readout","pmids":["12621024"],"is_preprint":false},{"year":2004,"finding":"RalA interacts with ZONAB (a Y-box transcription factor) in a GTP-dependent manner; the RalA-ZONAB complex increases with epithelial cell density and relieves ZONAB-mediated transcriptional repression; oncogenic Ras alleviates ZONAB repression in a RalA-dependent manner.","method":"Reverse Ras recruitment system; co-immunoprecipitation; transcriptional reporter assay","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 — novel interaction confirmed by co-IP with transcriptional functional readout","pmids":["15592429"],"is_preprint":false},{"year":2004,"finding":"RalA is associated with Weibel-Palade body dense granules in endothelial cells and is activated by cAMP-raising agents (epinephrine, forskolin) through a PKA-dependent mechanism; RalA activation is required for cAMP-mediated von Willebrand factor secretion.","method":"Cell-permeable peptide inhibition; PKA inhibitor (H-89); Ral-GTP loading assay; VWF secretion assay","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological and peptide inhibition with functional secretion readout","pmids":["15130921"],"is_preprint":false},{"year":2005,"finding":"Crystal structure of RalA bound to the Ral-binding domain (PH fold) of Exo84; Exo84 and Sec5 compete for the same binding site on active RalA via both switch regions; key interface residues were identified by mutagenesis.","method":"X-ray crystallography; mutagenesis; competitive binding assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with mutagenesis and biochemical competition assay","pmids":["15920473"],"is_preprint":false},{"year":2005,"finding":"RalA but not RalB promotes neurite branching in neurons via the exocyst complex; RalB promotes branching via phospholipase D; Ral-dependent branching is mediated by PKC-dependent phosphorylation of GAP-43.","method":"Active Ral overexpression; RNAi knockdown; dominant-negative mutants; effector-binding mutants; neuronal morphology assay","journal":"The Journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 2 — isoform-selective RNAi and effector mutant epistasis with defined morphological readout","pmids":["16330713"],"is_preprint":false},{"year":2006,"finding":"RalA is required for tumor initiation in human pancreatic cancer cells (anchorage-independent growth and tumorigenesis), while RalB is required for invasion and metastasis; these are distinct and divergent functions of the two highly similar GTPases.","method":"siRNA knockdown of RalA vs RalB; anchorage-independent growth assay; invasion assay; tail-vein injection metastasis model","journal":"Current biology : CB","confidence":"High","confidence_rationale":"Tier 2 — systematic siRNA comparison across 10 cell lines with in vivo tumor and metastasis readouts","pmids":["17174914"],"is_preprint":false},{"year":2007,"finding":"Insulin activates RalA in a PI 3-kinase-dependent manner in adipocytes; RalA is present in Glut4 vesicles and interacts with the exocyst complex to tether vesicles to the plasma membrane; RalA also interacts with Myo1c (a molecular motor), regulated by calmodulin, to function as a cargo receptor for Glut4 vesicle trafficking.","method":"RalA-GTP pulldown; siRNA knockdown; dominant-negative mutants; co-immunoprecipitation; glucose transport assay","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (pulldown, KD, co-IP, functional transport assay), single lab","pmids":["17765682"],"is_preprint":false},{"year":2007,"finding":"Activation of RalGEF/RalA pathway promotes prostate cancer metastasis specifically to bone; loss of RalA in PC3 cells inhibits bone metastasis but not subcutaneous tumor growth.","method":"RalA siRNA knockdown; in vivo bone metastasis assay; subcutaneous tumor growth comparison","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with in vivo metastasis readout","pmids":["17709381"],"is_preprint":false},{"year":2008,"finding":"RalA is required for tethering the exocyst to the cytokinetic furrow in early cytokinesis; RalB is then required for exocyst recruitment to the midbody for abscission; each Ral isoform is controlled by distinct RalGEF proteins.","method":"RNAi knockdown; live cell imaging; immunofluorescence of cytokinesis stages","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 — isoform-selective RNAi with defined spatial/temporal cytokinesis phenotypes","pmids":["18756269"],"is_preprint":false},{"year":2008,"finding":"RalA (and RalB) control localization of the exocyst complex to focal complexes during cell migration by regulating interaction between Sec5 and paxillin; reduction of RalA or RalB by RNAi alters exocyst localization without disrupting steady-state exocyst assembly.","method":"RNAi knockdown; co-immunoprecipitation; immunofluorescence localization","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 — RNAi with co-IP and localization readout","pmids":["18697830"],"is_preprint":false},{"year":2009,"finding":"Aurora-A kinase phosphorylates RalA at Ser194, promoting RalA activation and translocation from the plasma membrane; this phosphorylation activates RalBP1 effector and is required for Aurora-A-enhanced transformed cell growth.","method":"Kinase assay; phosphorylation site mutagenesis (S194); subcellular fractionation; transformation assay; tumor xenograft","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — kinase assay with mutagenesis, subcellular localization change, and in vivo tumorigenesis validation","pmids":["19901077"],"is_preprint":false},{"year":2009,"finding":"RalA mediates integrin-dependent membrane raft exocytosis via the exocyst complex; constitutively active RalA restores plasma membrane raft targeting to support anchorage-independent growth signaling.","method":"Dominant-active RalA; siRNA knockdown; membrane fractionation; growth signaling assay","journal":"Current biology : CB","confidence":"Medium","confidence_rationale":"Tier 2 — gain- and loss-of-function with fractionation and growth readout","pmids":["20005108"],"is_preprint":false},{"year":2009,"finding":"M-Sec induces membrane nanotube formation by interacting with RalA and the exocyst complex; blockage of M-Sec interaction with Ral or the exocyst attenuates nanotube formation.","method":"RNAi knockdown; dominant-negative interference; live cell imaging of nanotubes","journal":"Nature cell biology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic and dominant-negative interference with live imaging readout","pmids":["19935652"],"is_preprint":false},{"year":2009,"finding":"RalA and the exocyst complex associate with PAR-3 in a RalA-dependent manner during neuronal polarization; depletion of RalA or exocyst subunits inhibits axon formation, linking RalA-exocyst to PAR-3/aPKC polarity complex.","method":"Co-immunoprecipitation; RNAi knockdown; constitutively active RalA expression; neuronal morphology assay","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP with RNAi and functional polarity readout","pmids":["19383721"],"is_preprint":false},{"year":2010,"finding":"A Ral GAP complex (RGC1/RGC2) is identified as the GAP that activates RalA downstream of PI 3-kinase/Akt; Akt2 phosphorylates RGC2, inhibiting its GAP activity and thereby activating RalA for GLUT4 vesicle targeting in adipocytes.","method":"RGC identification and characterization; in vitro GTPase assay; Akt2 phosphorylation assay; siRNA knockdown; glucose uptake assay","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 1 — in vitro GAP assay with kinase phosphorylation and genetic validation","pmids":["21148297"],"is_preprint":false},{"year":2010,"finding":"RalA is a positive modulator of FcγR-mediated phagocytosis through PLD activation; RalA colocalizes with PLD1 and PLD2 at the phagocytic cup, and RalA co-immunoprecipitates with PLD isoforms in a stimulation-dependent manner.","method":"RNAi knockdown; PLD activity assay; co-immunoprecipitation; fluorescence microscopy of phagocytic cup","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP plus localization linked to functional phagocytosis readout","pmids":["20679536"],"is_preprint":false},{"year":2012,"finding":"RalA null mice develop exencephaly and embryonic lethality; double Rala/Ralb null embryos do not survive past gastrulation; in a KRAS-driven lung cancer model, either RalA or RalB alone is sufficient for tumor growth, but loss of both blocks tumor formation.","method":"Genetic knockout mice; Kras-driven lung cancer model; conditional deletion","journal":"Current biology : CB","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic deletion with developmental and tumor phenotypes, replicated across multiple genetic backgrounds","pmids":["23063435"],"is_preprint":false},{"year":2012,"finding":"RALA is activated downstream of RalGAPα2 loss in bladder cancer; exogenous wild-type RalGAPα2 (but not a catalytically inactive mutant) reduces RalA activity, cell migration in vitro, and lung metastasis in vivo; Ralgapa2 knockout promotes tumor invasion in mice.","method":"RalGAPα2 expression rescue; in vitro migration assay; mouse tumor model; KO mouse","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — catalytic mutant rescue and in vivo validation","pmids":["22450745"],"is_preprint":false},{"year":2013,"finding":"ROS activates RalA via the exchange factor RLF, which is in complex with JIP1 scaffold and JNK; active RalA then promotes assembly and activation of MLK3-MKK4-JNK onto the JIP1 scaffold, leading to FOXO activation; this mechanism is conserved in C. elegans.","method":"Co-immunoprecipitation; RNAi knockdown; FOXO reporter/localization assay; C. elegans genetics","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP with genetic epistasis in two organisms","pmids":["23770673"],"is_preprint":false},{"year":2014,"finding":"Small molecules (RBC8, BQU57) bind the GDP-bound form of RalA/RalB, inhibit Ral-RALBP1 interaction, and inhibit Ral-mediated cell spreading and anchorage-independent growth; binding confirmed by ITC, SPR, and NMR spectroscopy.","method":"Structure-based virtual screening; ITC; SPR; TROSY NMR; cell spreading assay; xenograft tumor growth","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — multiple biophysical methods confirming binding, functional cellular and in vivo validation","pmids":["25219851"],"is_preprint":false},{"year":2014,"finding":"In skeletal muscle, GARNL1/RalGAPα1 is a major RalGAP catalytic subunit; insulin activates RalA by Akt-mediated phosphorylation of GARNL1 at Thr735, causing 14-3-3 binding and GAP inactivation; knockdown of GARNL1 increases RalA activity and GLUT4 translocation.","method":"RalGAPα1 identification; phosphorylation site mutagenesis; 14-3-3 binding assay; siRNA knockdown; GLUT4 translocation assay","journal":"Cellular signalling","confidence":"High","confidence_rationale":"Tier 1 — phosphorylation site identified with mutagenesis and functional GLUT4 translocation readout","pmids":["24768767"],"is_preprint":false},{"year":2014,"finding":"Rab10 is activated by AS160 inactivation downstream of Akt; active Rab10 recruits the RalGEF Rlf/Rgl2 to GLUT4 vesicle membranes, activating RalA and thereby promoting maximal glucose transport; RalA is downstream of Rab10 in this cascade.","method":"GTP-loading assays; overexpression of membrane-tethered Rlf to bypass Rab10; siRNA knockdown; glucose transport assay","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis established by membrane-tethered rescue experiment","pmids":["25103239"],"is_preprint":false},{"year":2015,"finding":"TD-60/RCC2 exhibits GEF activity for RalA in vitro and in cells; TD-60 and RalA depletion cause spindle abnormalities and abnormal CPC accumulation; several TD-60-depletion phenotypes are rescued by GTP-locked RalA(Q72L), placing RalA in the CPC regulatory pathway.","method":"In vitro GEF assay; RNAi knockdown; GTP-locked rescue; immunofluorescence of mitotic cells","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — in vitro GEF assay confirmed in cells with epistasis rescue","pmids":["26158537"],"is_preprint":false},{"year":2015,"finding":"RAL-1 (RalA ortholog in C. elegans) localizes to secretory multivesicular bodies (MVBs) and is required for both MVB biogenesis and fusion with the plasma membrane for exosome secretion; in mammalian cells, RalA and RalB are both required for exosome-like vesicle secretion.","method":"Live imaging; quantitative electron microscopy; RNAi knockdown in C. elegans; RalA/B knockdown in mammalian cells; nanoparticle tracking analysis","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — localization with quantitative EM phenotype and functional validation in two model systems","pmids":["26459596"],"is_preprint":false},{"year":2016,"finding":"RalA activates PLD2 in endothelial cells; phosphatidic acid produced by PLD2 facilitates caveolae-mediated endocytosis and vesicle trafficking; RalA co-immunoprecipitates with caveolin-1 and filamin A upon albumin stimulation.","method":"siRNA knockdown of RalA; PLD2 inhibition; co-immunoprecipitation; TIRF microscopy; PA biosensor","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP, biosensor, and functional endocytosis readout","pmids":["27510034"],"is_preprint":false},{"year":2019,"finding":"RALA and RALB are required for internalization of the Wnt receptor Frizzled-7 in intestinal stem cells; genetic deletion of either reduces ISC function and Lgr5 positivity, while dual deletion causes rapid crypt death.","method":"Genetic KO mouse; Drosophila genetics; Frizzled-7 internalization assay; intestinal organoid culture","journal":"Cell stem cell","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic deletion with receptor internalization mechanistic readout, conserved across species","pmids":["30853556"],"is_preprint":false},{"year":2021,"finding":"RalA and RalB control biogenesis and secretion of pro-metastatic extracellular vesicles through phospholipase D1; RalA/B-depleted cells produce EVs with elevated MCAM/CD146, reducing organotropic EV targeting and pre-metastatic niche formation.","method":"RalA/B knockdown; EV nanoparticle tracking; in vivo EV uptake assay; proteomics of EVs","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 — systematic RalA/B depletion with EV characterization and in vivo validation","pmids":["33404012"],"is_preprint":false},{"year":2024,"finding":"RalA expression and activity are increased in white adipocytes after high-fat diet; RalA drives mitochondrial fragmentation by reversing the inhibitory Ser637 phosphorylation of Drp1, increasing fission; adipocyte-specific RalA deletion prevents fragmentation, reduces weight gain, and increases fatty acid oxidation.","method":"Conditional adipocyte-specific RalA KO mouse; Drp1-Ser637 phosphorylation assay; mitochondrial morphology imaging; metabolic phenotyping","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 2 — tissue-specific genetic KO with defined molecular mechanism (Drp1 dephosphorylation) and metabolic phenotype","pmids":["38286821"],"is_preprint":false}],"current_model":"RALA is a membrane-localized small GTPase that cycles between GDP- and GTP-bound states under control of RalGEFs (activated by Ras, Rap1, Ca2+/calmodulin, or Rab10) and RalGAPs (inhibited by Akt-dependent phosphorylation); GTP-RalA engages multiple effectors including the exocyst complex (via Sec5 and Exo84) to drive vesicle trafficking, GLUT4 translocation, cytokinesis, and membrane nanotube formation, RLIP76/RalBP1 to regulate Rac/Cdc42 and stress signaling, phospholipase D1/D2 to generate phosphatidic acid for caveolae endocytosis and exosome biogenesis, filamin to induce filopodia downstream of Cdc42, and the JIP1 scaffold to activate JNK/FOXO; Aurora-A phosphorylates RalA at Ser194 to promote its plasma membrane-to-cytoplasm translocation and effector activation, while in obesity RalA promotes mitochondrial fission by reversing inhibitory Drp1-Ser637 phosphorylation."},"narrative":{"teleology":[{"year":1986,"claim":"The identity of RALA as a new Ras-related GTPase was established, revealing the existence of a distinct branch of the Ras superfamily with predicted membrane localization.","evidence":"cDNA cloning from simian B-lymphocyte library with sequence analysis identifying GTP-binding domains and C-terminal cysteine for prenylation","pmids":["3023062"],"confidence":"High","gaps":["No effectors or upstream regulators identified","No functional role demonstrated"]},{"year":1990,"claim":"Biochemical characterization showed RalA possesses low intrinsic GTPase activity and slow GDP exchange, and that activating mutations analogous to oncogenic Ras mutations alter these properties, establishing RalA as a bona fide GTP-hydrolyzing molecular switch.","evidence":"In vitro GTPase and exchange assays with purified recombinant RalA; site-directed mutagenesis; NMR spectroscopy","pmids":["2108160"],"confidence":"High","gaps":["No upstream activator (GEF) identified","No downstream effectors known"]},{"year":1991,"claim":"Discovery of a Ral-specific GAP in brain and testis demonstrated that RalA cycling is regulated by a dedicated GTPase-activating protein distinct from those acting on Ras, Rho, or Rap.","evidence":"Biochemical fractionation and in vitro GTPase assay with substrate specificity controls","pmids":["1903395"],"confidence":"Medium","gaps":["Molecular identity of the GAP not determined","Single biochemical fractionation without molecular cloning"]},{"year":1995,"claim":"Identification of the first RalA effectors—phospholipase D and RLIP76/RalBP1—revealed that RalA connects to lipid signaling (PLD) and Rho-family GTPase regulation (via RLIP76's GAP activity toward Rac1/Cdc42), establishing two major downstream branches.","evidence":"Immunoprecipitation of PLD with RalA, deletion mutagenesis (PLD); yeast two-hybrid and in vitro pulldown with GAP activity assay (RLIP76)","pmids":["7477381","7673236"],"confidence":"High","gaps":["Physiological contexts for PLD and RLIP76 signaling undefined","No structural detail on effector contacts"]},{"year":1996,"claim":"Epistasis experiments with constitutively active and dominant-negative RalA showed that Ral operates as a Ras effector pathway distinct from Raf, contributing to oncogenic transformation, and that prenylation of both Ras and RalA is required for efficient signal relay through RalGDS.","evidence":"Gain- and loss-of-function mutant overexpression in transformation assays; GDP/GTP exchange assays requiring prenylation","pmids":["8631302","8702675"],"confidence":"High","gaps":["Identity and diversity of RalGEF proteins incompletely mapped","Whether Ral operates independently of Ras not resolved"]},{"year":1998,"claim":"Two Ras-independent activation modes for RalA were uncovered: Ca²⁺/PLC-dependent activation by LPA/EGF, and RalA scaffolding of an Arf–PLD complex, broadening the upstream inputs and mechanistic outputs of the pathway.","evidence":"Ral-GTP loading assays with dominant-negative Ras, Ca²⁺ ionophore, PLC inhibitor; GST-RalA pulldown identifying Arf co-association; Brefeldin A and dominant-negative Arf perturbation","pmids":["9663394","9520417"],"confidence":"Medium","gaps":["Specific RalGEF linking Ca²⁺ to RalA not identified","Stoichiometry of the Ral-Arf-PLD complex undefined"]},{"year":1999,"claim":"RalA was placed downstream of Cdc42 in filopodium formation through direct GTP-dependent binding to filamin, and was shown to contribute to Ras-driven tumor invasion by controlling uPA and MMP expression.","evidence":"GTP-specific binding assay and filamin-deficient cell rescue; dominant-negative RalA blocking MMP overproduction and in vivo tumorigenesis","pmids":["10051605","10467419"],"confidence":"High","gaps":["How Cdc42 activates RalA mechanistically not established","Filamin interaction structure unresolved"]},{"year":2002,"claim":"The exocyst subunit Sec5 was identified as a direct GTP-dependent effector of RalA, and β-arrestin was shown to sequester RalGDS until receptor stimulation, revealing a new effector arm (exocyst) and a Ras-independent activation mechanism (β-arrestin/GPCR).","evidence":"Yeast two-hybrid and co-immunoprecipitation confirming GTP-specific Sec5 binding with filopod functional readout; co-IP of β-arrestin/RalGDS from primary PMNs with Ral-GTP assay","pmids":["11744922","12105416"],"confidence":"High","gaps":["Structural basis of RalA–Sec5 not yet determined at this time","Full set of exocyst subunits engaging RalA unknown"]},{"year":2003,"claim":"The crystal structure of the RalA·GppNHp–Sec5 complex at 2.1 Å revealed that Sec5 adopts an immunoglobulin-like fold contacting both switch regions of RalA, providing the first atomic-resolution view of how RalA recruits the exocyst.","evidence":"X-ray crystallography with ITC and mutagenesis validation","pmids":["12839989"],"confidence":"High","gaps":["Structure of RalA with other effectors not yet solved","Mechanism of exocyst complex assembly upon RalA binding unknown"]},{"year":2005,"claim":"Crystal structure of RalA bound to Exo84's PH-fold Ral-binding domain showed that Sec5 and Exo84 compete for the same switch-region surface on RalA, establishing that RalA engages two distinct exocyst subunits in a mutually exclusive manner to potentially coordinate sequential trafficking steps.","evidence":"X-ray crystallography; competitive binding assay; mutagenesis","pmids":["15920473"],"confidence":"High","gaps":["Functional consequence of Sec5 vs Exo84 engagement in specific trafficking events unclear","Full exocyst reconstitution with RalA not performed"]},{"year":2007,"claim":"RalA was established as a critical node in insulin-stimulated GLUT4 vesicle exocytosis: insulin activates RalA via PI3K, and RalA then bridges GLUT4 vesicles to the exocyst and the motor protein Myo1c for plasma membrane tethering.","evidence":"Ral-GTP pulldown, siRNA knockdown, co-IP with Myo1c, dominant-negative mutants, glucose transport assay in adipocytes","pmids":["17765682"],"confidence":"High","gaps":["How RalA coordinates with Rab proteins on the same vesicle not resolved","Precise step at which RalA acts (tethering vs fusion) ambiguous"]},{"year":2006,"claim":"Systematic comparison in pancreatic cancer cells revealed that RalA is selectively required for anchorage-independent growth and tumor initiation, while RalB drives invasion and metastasis, demonstrating functional divergence despite >80% sequence identity.","evidence":"siRNA knockdown of RalA vs RalB across 10 cell lines; anchorage-independent growth; tail-vein metastasis model","pmids":["17174914"],"confidence":"High","gaps":["Molecular basis of isoform-specific effector engagement unclear","Whether isoform divergence is tissue-dependent not fully tested"]},{"year":2008,"claim":"RalA was shown to tether the exocyst to the cytokinetic furrow during early cytokinesis and to regulate exocyst targeting to focal complexes during cell migration via Sec5–paxillin interaction, extending RalA-exocyst function to cell division and motility.","evidence":"RNAi knockdown with live cell imaging of cytokinesis stages; co-IP of exocyst-paxillin with RalA depletion","pmids":["18756269","18697830"],"confidence":"Medium","gaps":["RalGEF identity at the furrow not determined","Whether RalA and RalB have sequential roles confirmed only partially"]},{"year":2009,"claim":"Aurora-A was identified as a kinase that phosphorylates RalA at Ser194, promoting RalA translocation from the plasma membrane and activating RalBP1-dependent effector signaling required for transformation—revealing a mitotic kinase input to Ral signaling.","evidence":"In vitro kinase assay; S194 mutagenesis; subcellular fractionation; tumor xenograft","pmids":["19901077"],"confidence":"High","gaps":["Phosphatase opposing Aurora-A at Ser194 unknown","Whether Ser194 phosphorylation affects exocyst or PLD arms not tested"]},{"year":2010,"claim":"The molecular identity of the RalGAP complex (RGC1/RGC2) was established, and Akt2-mediated phosphorylation of RGC2 was shown to inhibit GAP activity, providing the mechanistic link between insulin/PI3K/Akt signaling and RalA activation for GLUT4 translocation.","evidence":"In vitro GAP assay; Akt2 phosphorylation site identification; siRNA knockdown; glucose uptake assay","pmids":["21148297"],"confidence":"High","gaps":["Whether other kinases regulate RGC under different stimuli unclear","Structural basis of RGC catalysis unknown"]},{"year":2013,"claim":"A ROS-responsive pathway was delineated in which the RalGEF RLF activates RalA on a JIP1 scaffold, promoting assembly of a MLK3-MKK4-JNK cascade and FOXO activation—a mechanism conserved in C. elegans—linking RalA to oxidative stress and longevity signaling.","evidence":"Co-immunoprecipitation; RNAi knockdown; FOXO reporter assay; C. elegans epistasis","pmids":["23770673"],"confidence":"Medium","gaps":["Direct binding between RalA and JIP1 not demonstrated in vitro","Physiological ROS levels required for this pathway not defined"]},{"year":2014,"claim":"Small-molecule inhibitors (RBC8, BQU57) that bind GDP-bound RalA and block effector engagement were developed and validated biophysically and in vivo, providing first chemical tools to pharmacologically target the Ral pathway.","evidence":"Virtual screening; ITC, SPR, TROSY-NMR binding confirmation; cell spreading and xenograft tumor growth inhibition","pmids":["25219851"],"confidence":"High","gaps":["Selectivity over RalB not fully characterized","In vivo pharmacokinetics and therapeutic window undefined"]},{"year":2015,"claim":"RalA was placed in the chromosomal passenger complex (CPC) regulatory pathway through TD-60/RCC2 acting as a RalA GEF during mitosis, and in exosome biogenesis through localization to multivesicular bodies and requirement for MVB fusion with the plasma membrane.","evidence":"In vitro GEF assay with RCC2; RNAi and GTP-locked rescue of spindle phenotypes; EM and live imaging of MVBs in C. elegans; nanoparticle tracking in mammalian cells","pmids":["26158537","26459596"],"confidence":"High","gaps":["Whether RalA directly associates with CPC components unknown","Step at which RalA acts in MVB biogenesis vs fusion not distinguished cleanly"]},{"year":2019,"claim":"In vivo genetic deletion in intestinal epithelium showed that RalA (and RalB) are required for Frizzled-7 internalization and intestinal stem cell maintenance, positioning Ral GTPases as essential regulators of Wnt receptor endocytosis in tissue homeostasis.","evidence":"Conditional KO mouse; Drosophila genetics; Frizzled-7 internalization assay; organoid culture","pmids":["30853556"],"confidence":"High","gaps":["Effector pathway mediating Frizzled-7 internalization (exocyst vs PLD) not resolved","Whether RalA acts at internalization or recycling step unclear"]},{"year":2024,"claim":"In obesity, RalA activity increases in white adipocytes and drives mitochondrial fragmentation by reversing inhibitory Drp1-Ser637 phosphorylation, identifying a previously unrecognized metabolic role for RalA in controlling mitochondrial dynamics.","evidence":"Adipocyte-specific conditional RalA KO mouse; Drp1-Ser637 phosphorylation assay; mitochondrial imaging; metabolic phenotyping","pmids":["38286821"],"confidence":"High","gaps":["Phosphatase recruited by RalA to dephosphorylate Drp1-Ser637 not identified","Whether this mechanism operates in other metabolically active tissues unknown"]},{"year":null,"claim":"Key unresolved questions include: the structural basis of RalA selectivity for specific effectors versus RalB, the identity of phosphatases that reverse Aurora-A and Akt regulatory inputs, how competing effector interactions (Sec5 vs Exo84 vs RLIP76 vs PLD) are spatiotemporally resolved within a single cell, and whether the metabolic (Drp1) function is a direct or indirect consequence of RalA effector engagement.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structure of full exocyst with RalA","No phosphatase for Ser194 identified","Isoform-specific effector selection mechanism unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003924","term_label":"GTPase activity","supporting_discovery_ids":[0,1,2]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[3,4,26,47]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,6,26,30]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[15,22,26,43]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[30]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,5,8,18,38]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[15,16,26,43,44,45]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[28,42]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,25,27,36,37]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[26,34,40,47]},{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[26,40,41]}],"complexes":["Exocyst complex"],"partners":["SEC5","EXO84","RLIP76","PLD1","PLD2","FLNA","RALGDS","MYO1C"],"other_free_text":[]},"mechanistic_narrative":"RALA is a Ras-related small GTPase that functions as a central signaling hub linking growth factor, calcium, and Ras-dependent inputs to vesicle trafficking, cytoskeletal remodeling, and transcriptional regulation. Cycling between GDP- and GTP-bound states under the control of RalGEFs (activated by Ras, Ca²⁺/calmodulin, β-arrestin release, Rab10, and RCC2/TD-60) and RalGAP complexes (inhibited by Akt-mediated phosphorylation), GTP-loaded RalA engages a suite of effectors: the exocyst complex (via Sec5 and Exo84) to drive GLUT4 vesicle tethering, Weibel-Palade body exocytosis, cytokinesis, exosome secretion, Frizzled-7 internalization, and membrane nanotube formation; RLIP76/RalBP1 to regulate Rac/Cdc42 signaling, JNK-FOXO activation, and heat-shock responses; phospholipase D1/D2 to generate phosphatidic acid for caveolae endocytosis, phagocytosis, and extracellular vesicle biogenesis; and filamin to promote filopodia downstream of Cdc42 [PMID:7477381, PMID:7673236, PMID:11744922, PMID:15920473, PMID:10051605, PMID:17765682, PMID:26459596, PMID:30853556, PMID:18756269, PMID:23770673]. Aurora-A phosphorylates RalA at Ser194 to promote its translocation from the plasma membrane and enhance effector engagement during oncogenic growth [PMID:19901077]. RalA is essential for Ras-driven tumorigenesis and anchorage-independent growth in pancreatic and lung cancer models, RalA-null mice exhibit exencephaly and embryonic lethality, and in obesity RalA drives mitochondrial fission by reversing Drp1-Ser637 phosphorylation in adipocytes [PMID:25219851, PMID:23063435, PMID:38286821]."},"prefetch_data":{"uniprot":{"accession":"P11233","full_name":"Ras-related protein Ral-A","aliases":[],"length_aa":206,"mass_kda":23.6,"function":"Multifunctional GTPase involved in a variety of cellular processes including gene expression, cell migration, cell proliferation, oncogenic transformation and membrane trafficking. Accomplishes its multiple functions by interacting with distinct downstream effectors (PubMed:18756269, PubMed:19306925, PubMed:20005108, PubMed:21822277, PubMed:30500825). Acts as a GTP sensor for GTP-dependent exocytosis of dense core vesicles. The RALA-exocyst complex regulates integrin-dependent membrane raft exocytosis and growth signaling (PubMed:20005108). Key regulator of LPAR1 signaling and competes with GRK2 for binding to LPAR1 thus affecting the signaling properties of the receptor. Required for anchorage-independent proliferation of transformed cells (PubMed:19306925). During mitosis, supports the stabilization and elongation of the intracellular bridge between dividing cells. Cooperates with EXOC2 to recruit other components of the exocyst to the early midbody (PubMed:18756269). During mitosis, also controls mitochondrial fission by recruiting to the mitochondrion RALBP1, which mediates the phosphorylation and activation of DNM1L by the mitotic kinase cyclin B-CDK1 (PubMed:21822277)","subcellular_location":"Cell membrane; Cleavage furrow; Midbody, Midbody ring; Mitochondrion","url":"https://www.uniprot.org/uniprotkb/P11233/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RALA","classification":"Not Classified","n_dependent_lines":27,"n_total_lines":1208,"dependency_fraction":0.022350993377483443},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CALM1","stoichiometry":0.2},{"gene":"CALM2","stoichiometry":0.2},{"gene":"CALM3","stoichiometry":0.2},{"gene":"SLC16A1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/RALA","total_profiled":1310},"omim":[{"mim_id":"619311","title":"HIATT-NEU-COOPER NEURODEVELOPMENTAL SYNDROME; HINCONS","url":"https://www.omim.org/entry/619311"},{"mim_id":"618836","title":"RAL GTPase-ACTIVATING PROTEIN, CATALYTIC SUBUNIT ALPHA-2; RALGAPA2","url":"https://www.omim.org/entry/618836"},{"mim_id":"618833","title":"RAL GTPase-ACTIVATING PROTEIN, NONCATALYTIC SUBUNIT BETA; RALGAPB","url":"https://www.omim.org/entry/618833"},{"mim_id":"618797","title":"NEURODEVELOPMENTAL DISORDER WITH HYPOTONIA, NEONATAL RESPIRATORY INSUFFICIENCY, AND THERMODYSREGULATION; NEDHRIT","url":"https://www.omim.org/entry/618797"},{"mim_id":"616927","title":"EXOCYST COMPLEX COMPONENT 3-LIKE 2; EXOC3L2","url":"https://www.omim.org/entry/616927"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Focal adhesion sites","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/RALA"},"hgnc":{"alias_symbol":[],"prev_symbol":["RAL"]},"alphafold":{"accession":"P11233","domains":[{"cath_id":"3.40.50.300","chopping":"13-203","consensus_level":"high","plddt":92.3039,"start":13,"end":203}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P11233","model_url":"https://alphafold.ebi.ac.uk/files/AF-P11233-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P11233-F1-predicted_aligned_error_v6.png","plddt_mean":89.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RALA","jax_strain_url":"https://www.jax.org/strain/search?query=RALA"},"sequence":{"accession":"P11233","fasta_url":"https://rest.uniprot.org/uniprotkb/P11233.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P11233/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P11233"}},"corpus_meta":[{"pmid":"10051605","id":"PMC_10051605","title":"The small GTPase RalA targets filamin to induce filopodia.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10051605","citation_count":358,"is_preprint":false},{"pmid":"19935652","id":"PMC_19935652","title":"M-Sec promotes membrane nanotube formation by interacting with Ral and the exocyst complex.","date":"2009","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19935652","citation_count":322,"is_preprint":false},{"pmid":"8631302","id":"PMC_8631302","title":"Ral-GTPases mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation.","date":"1996","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8631302","citation_count":294,"is_preprint":false},{"pmid":"7673236","id":"PMC_7673236","title":"Bridging Ral GTPase to Rho pathways. RLIP76, a Ral effector with CDC42/Rac GTPase-activating protein activity.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7673236","citation_count":291,"is_preprint":false},{"pmid":"9843482","id":"PMC_9843482","title":"All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ral.","date":"1998","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9843482","citation_count":280,"is_preprint":false},{"pmid":"7477381","id":"PMC_7477381","title":"Involvement of Ral GTPase in v-Src-induced phospholipase D activation.","date":"1995","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7477381","citation_count":244,"is_preprint":false},{"pmid":"3023062","id":"PMC_3023062","title":"The ral gene: a new ras related gene isolated by the use of a synthetic probe.","date":"1986","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/3023062","citation_count":240,"is_preprint":false},{"pmid":"11744922","id":"PMC_11744922","title":"The exocyst complex binds the small GTPase RalA to mediate filopodia formation.","date":"2002","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11744922","citation_count":208,"is_preprint":false},{"pmid":"17174914","id":"PMC_17174914","title":"Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells.","date":"2006","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/17174914","citation_count":191,"is_preprint":false},{"pmid":"8987400","id":"PMC_8987400","title":"Evidence for a Ras/Ral signaling cascade.","date":"1996","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/8987400","citation_count":179,"is_preprint":false},{"pmid":"26459596","id":"PMC_26459596","title":"RAL-1 controls multivesicular body biogenesis and exosome secretion.","date":"2015","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26459596","citation_count":176,"is_preprint":false},{"pmid":"17765682","id":"PMC_17765682","title":"Activation of RalA is required for insulin-stimulated Glut4 trafficking to the plasma membrane via the exocyst and the motor protein Myo1c.","date":"2007","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/17765682","citation_count":171,"is_preprint":false},{"pmid":"10072355","id":"PMC_10072355","title":"Ras caught in another affair: the exchange factors for Ral.","date":"1999","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/10072355","citation_count":127,"is_preprint":false},{"pmid":"25219851","id":"PMC_25219851","title":"Discovery and characterization of small molecules that target the GTPase Ral.","date":"2014","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/25219851","citation_count":123,"is_preprint":false},{"pmid":"15920473","id":"PMC_15920473","title":"Exo84 and Sec5 are competitive regulatory Sec6/8 effectors to the RalA GTPase.","date":"2005","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/15920473","citation_count":122,"is_preprint":false},{"pmid":"10675331","id":"PMC_10675331","title":"An EGF receptor/Ral-GTPase signaling cascade regulates c-Src activity and substrate specificity.","date":"2000","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10675331","citation_count":120,"is_preprint":false},{"pmid":"19609003","id":"PMC_19609003","title":"Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells.","date":"2009","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/19609003","citation_count":120,"is_preprint":false},{"pmid":"12105416","id":"PMC_12105416","title":"Beta-arrestins regulate a Ral-GDS Ral effector pathway that mediates cytoskeletal reorganization.","date":"2002","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12105416","citation_count":112,"is_preprint":false},{"pmid":"24063364","id":"PMC_24063364","title":"microRNA-140 targets RALA and regulates chondrogenic differentiation of human mesenchymal stem cells by translational enhancement of SOX9 and ACAN.","date":"2013","source":"Stem cells and development","url":"https://pubmed.ncbi.nlm.nih.gov/24063364","citation_count":112,"is_preprint":false},{"pmid":"2457862","id":"PMC_2457862","title":"Expression of the ras-related ralA, rho12 and rab genes in adult mouse tissues.","date":"1988","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/2457862","citation_count":111,"is_preprint":false},{"pmid":"16103060","id":"PMC_16103060","title":"RalA and RalB: antagonistic relatives in cancer cell migration.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16103060","citation_count":109,"is_preprint":false},{"pmid":"38286821","id":"PMC_38286821","title":"Obesity causes mitochondrial fragmentation and dysfunction in white adipocytes due to RalA activation.","date":"2024","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/38286821","citation_count":107,"is_preprint":false},{"pmid":"9520417","id":"PMC_9520417","title":"Functional association between Arf and RalA in active phospholipase D complex.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9520417","citation_count":102,"is_preprint":false},{"pmid":"11840339","id":"PMC_11840339","title":"Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11840339","citation_count":102,"is_preprint":false},{"pmid":"12839989","id":"PMC_12839989","title":"Structural basis of the interaction between RalA and Sec5, a subunit of the sec6/8 complex.","date":"2003","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12839989","citation_count":98,"is_preprint":false},{"pmid":"19901077","id":"PMC_19901077","title":"Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA.","date":"2009","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19901077","citation_count":97,"is_preprint":false},{"pmid":"18756269","id":"PMC_18756269","title":"Distinct roles of RalA and RalB in the progression of cytokinesis are supported by distinct RalGEFs.","date":"2008","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/18756269","citation_count":96,"is_preprint":false},{"pmid":"33404012","id":"PMC_33404012","title":"Ral GTPases promote breast cancer metastasis by controlling biogenesis and organ targeting of exosomes.","date":"2021","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/33404012","citation_count":94,"is_preprint":false},{"pmid":"24748661","id":"PMC_24748661","title":"RalR (a DNase) and RalA (a small RNA) form a type I toxin-antitoxin system in Escherichia coli.","date":"2014","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/24748661","citation_count":93,"is_preprint":false},{"pmid":"2550440","id":"PMC_2550440","title":"Identification of the ral and rac1 gene products, low molecular mass GTP-binding proteins from human platelets.","date":"1989","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2550440","citation_count":91,"is_preprint":false},{"pmid":"12621024","id":"PMC_12621024","title":"HSF-1 interacts with Ral-binding protein 1 in a stress-responsive, multiprotein complex with HSP90 in vivo.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12621024","citation_count":90,"is_preprint":false},{"pmid":"17709381","id":"PMC_17709381","title":"Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17709381","citation_count":89,"is_preprint":false},{"pmid":"10611224","id":"PMC_10611224","title":"Phospholipase D and RalA cooperate with the epidermal growth factor receptor to transform 3Y1 rat fibroblasts.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10611224","citation_count":88,"is_preprint":false},{"pmid":"10896938","id":"PMC_10896938","title":"p130Cas regulates the activity of AND-34, a novel Ral, Rap1, and R-Ras guanine nucleotide exchange factor.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10896938","citation_count":86,"is_preprint":false},{"pmid":"15592429","id":"PMC_15592429","title":"RalA interacts with ZONAB in a cell density-dependent manner and regulates its transcriptional activity.","date":"2004","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/15592429","citation_count":85,"is_preprint":false},{"pmid":"21148297","id":"PMC_21148297","title":"A Ral GAP complex links PI 3-kinase/Akt signaling to RalA activation in insulin action.","date":"2010","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/21148297","citation_count":84,"is_preprint":false},{"pmid":"10848592","id":"PMC_10848592","title":"Involvement of Ras and Ral in chemotactic migration of skeletal myoblasts.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10848592","citation_count":84,"is_preprint":false},{"pmid":"16330713","id":"PMC_16330713","title":"Ral GTPases regulate neurite branching through GAP-43 and the exocyst complex.","date":"2005","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16330713","citation_count":83,"is_preprint":false},{"pmid":"25219551","id":"PMC_25219551","title":"Ral small GTPase signaling and oncogenesis: More than just 15minutes of fame.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25219551","citation_count":81,"is_preprint":false},{"pmid":"18697830","id":"PMC_18697830","title":"Ral-regulated interaction between Sec5 and paxillin targets Exocyst to focal complexes during cell migration.","date":"2008","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/18697830","citation_count":80,"is_preprint":false},{"pmid":"27979747","id":"PMC_27979747","title":"DNA vaccination for cervical cancer; a novel technology platform of RALA mediated gene delivery via polymeric microneedles.","date":"2016","source":"Nanomedicine : nanotechnology, biology, and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27979747","citation_count":80,"is_preprint":false},{"pmid":"29196555","id":"PMC_29196555","title":"RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer.","date":"2018","source":"Pharmacological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/29196555","citation_count":78,"is_preprint":false},{"pmid":"11861368","id":"PMC_11861368","title":"The role of Ral A in epidermal growth factor receptor-regulated cell motility.","date":"2002","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11861368","citation_count":78,"is_preprint":false},{"pmid":"10454580","id":"PMC_10454580","title":"Differential roles of Akt, Rac, and Ral in R-Ras-mediated cellular transformation, adhesion, and survival.","date":"1999","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10454580","citation_count":76,"is_preprint":false},{"pmid":"31299353","id":"PMC_31299353","title":"DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen.","date":"2019","source":"Acta biomaterialia","url":"https://pubmed.ncbi.nlm.nih.gov/31299353","citation_count":73,"is_preprint":false},{"pmid":"10467419","id":"PMC_10467419","title":"RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10467419","citation_count":70,"is_preprint":false},{"pmid":"17875936","id":"PMC_17875936","title":"Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17875936","citation_count":68,"is_preprint":false},{"pmid":"10364219","id":"PMC_10364219","title":"Effector recognition by the small GTP-binding proteins Ras and Ral.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10364219","citation_count":68,"is_preprint":false},{"pmid":"21199803","id":"PMC_21199803","title":"Activation and involvement of Ral GTPases in colorectal cancer.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21199803","citation_count":67,"is_preprint":false},{"pmid":"17606711","id":"PMC_17606711","title":"Expression of ral GTPases, their effectors, and activators in human bladder cancer.","date":"2007","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17606711","citation_count":66,"is_preprint":false},{"pmid":"23063435","id":"PMC_23063435","title":"Genetic deletion of RALA and RALB small GTPases reveals redundant functions in development and tumorigenesis.","date":"2012","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/23063435","citation_count":65,"is_preprint":false},{"pmid":"19383721","id":"PMC_19383721","title":"RalA and the exocyst complex influence neuronal polarity through PAR-3 and aPKC.","date":"2009","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/19383721","citation_count":65,"is_preprint":false},{"pmid":"20478380","id":"PMC_20478380","title":"RalGDS family members couple Ras to Ral signalling and that's not all.","date":"2010","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/20478380","citation_count":65,"is_preprint":false},{"pmid":"9663394","id":"PMC_9663394","title":"Ras-independent activation of Ral by a Ca(2+)-dependent pathway.","date":"1998","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/9663394","citation_count":65,"is_preprint":false},{"pmid":"16781882","id":"PMC_16781882","title":"Ral: mediator of membrane trafficking.","date":"2006","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16781882","citation_count":65,"is_preprint":false},{"pmid":"11046144","id":"PMC_11046144","title":"Ras-dependent regulation of c-Jun phosphorylation is mediated by the Ral guanine nucleotide exchange factor-Ral pathway.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11046144","citation_count":63,"is_preprint":false},{"pmid":"9099691","id":"PMC_9099691","title":"Characterization of Ral GDP dissociation stimulator-like (RGL) activities to regulate c-fos promoter and the GDP/GTP exchange of Ral.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9099691","citation_count":61,"is_preprint":false},{"pmid":"22442671","id":"PMC_22442671","title":"miR-181a post-transcriptionally downregulates oncogenic RalA and contributes to growth inhibition and apoptosis in chronic myelogenous leukemia (CML).","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22442671","citation_count":61,"is_preprint":false},{"pmid":"20005108","id":"PMC_20005108","title":"RalA-exocyst complex regulates integrin-dependent membrane raft exocytosis and growth signaling.","date":"2009","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/20005108","citation_count":60,"is_preprint":false},{"pmid":"29510205","id":"PMC_29510205","title":"DNA vaccination for cervical cancer: Strategic optimisation of RALA mediated gene delivery from a biodegradable microneedle system.","date":"2018","source":"European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V","url":"https://pubmed.ncbi.nlm.nih.gov/29510205","citation_count":56,"is_preprint":false},{"pmid":"27846370","id":"PMC_27846370","title":"Dissolving microneedles for DNA vaccination: Improving functionality via polymer characterization and RALA complexation.","date":"2016","source":"Human vaccines & immunotherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/27846370","citation_count":53,"is_preprint":false},{"pmid":"1903395","id":"PMC_1903395","title":"Characterization of a GTPase-activating protein for the Ras-related Ral protein.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1903395","citation_count":49,"is_preprint":false},{"pmid":"22450745","id":"PMC_22450745","title":"Downregulation of Ral GTPase-activating protein promotes tumor invasion and metastasis of bladder cancer.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22450745","citation_count":49,"is_preprint":false},{"pmid":"27875100","id":"PMC_27875100","title":"The Small GTPase Ral orchestrates MVB biogenesis and exosome secretion.","date":"2016","source":"Small GTPases","url":"https://pubmed.ncbi.nlm.nih.gov/27875100","citation_count":48,"is_preprint":false},{"pmid":"3023633","id":"PMC_3023633","title":"Modification enhancement by the restriction alleviation protein (Ral) of bacteriophage lambda.","date":"1986","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3023633","citation_count":48,"is_preprint":false},{"pmid":"12509462","id":"PMC_12509462","title":"Elevated phospholipase D activity in H-Ras- but not K-Ras-transformed cells by the synergistic action of RalA and ARF6.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12509462","citation_count":46,"is_preprint":false},{"pmid":"2108160","id":"PMC_2108160","title":"Guanine nucleotide binding properties of the mammalian RalA protein produced in Escherichia coli.","date":"1990","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2108160","citation_count":45,"is_preprint":false},{"pmid":"17344481","id":"PMC_17344481","title":"R-Ras regulates exocytosis by Rgl2/Rlf-mediated activation of RalA on endosomes.","date":"2007","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/17344481","citation_count":45,"is_preprint":false},{"pmid":"22820503","id":"PMC_22820503","title":"Role of RalA downstream of Rac1 in insulin-dependent glucose uptake in muscle cells.","date":"2012","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/22820503","citation_count":43,"is_preprint":false},{"pmid":"29047224","id":"PMC_29047224","title":"Ral signaling pathway in health and cancer.","date":"2017","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29047224","citation_count":41,"is_preprint":false},{"pmid":"8702675","id":"PMC_8702675","title":"Post-translational modifications of Ras and Ral are important for the action of Ral GDP dissociation stimulator.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8702675","citation_count":40,"is_preprint":false},{"pmid":"26158537","id":"PMC_26158537","title":"TD-60 links RalA GTPase function to the CPC in mitosis.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26158537","citation_count":40,"is_preprint":false},{"pmid":"15130921","id":"PMC_15130921","title":"Small GTP-binding protein Ral is involved in cAMP-mediated release of von Willebrand factor from endothelial cells.","date":"2004","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15130921","citation_count":40,"is_preprint":false},{"pmid":"31676385","id":"PMC_31676385","title":"Delivery of RALA/siFKBPL nanoparticles via electrospun bilayer nanofibres: An innovative angiogenic therapy for wound repair.","date":"2019","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/31676385","citation_count":39,"is_preprint":false},{"pmid":"17000765","id":"PMC_17000765","title":"The Ral/exocyst effector complex counters c-Jun N-terminal kinase-dependent apoptosis in Drosophila melanogaster.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17000765","citation_count":39,"is_preprint":false},{"pmid":"11397694","id":"PMC_11397694","title":"Small GTP-binding protein Ral modulates regulated exocytosis of von Willebrand factor by endothelial cells.","date":"2001","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11397694","citation_count":39,"is_preprint":false},{"pmid":"22084305","id":"PMC_22084305","title":"The Rap1-Rgl-Ral signaling network regulates neuroblast cortical polarity and spindle orientation.","date":"2011","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/22084305","citation_count":38,"is_preprint":false},{"pmid":"25103239","id":"PMC_25103239","title":"A Rab10:RalA G protein cascade regulates insulin-stimulated glucose uptake in adipocytes.","date":"2014","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/25103239","citation_count":37,"is_preprint":false},{"pmid":"25557115","id":"PMC_25557115","title":"The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer.","date":"2015","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/25557115","citation_count":35,"is_preprint":false},{"pmid":"22586063","id":"PMC_22586063","title":"Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22586063","citation_count":35,"is_preprint":false},{"pmid":"26092850","id":"PMC_26092850","title":"A rapid, membrane-dependent pathway directs furrow formation through RalA in the early Drosophila embryo.","date":"2015","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/26092850","citation_count":34,"is_preprint":false},{"pmid":"22580611","id":"PMC_22580611","title":"PGE2 promotes renal carcinoma cell invasion through activated RalA.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22580611","citation_count":34,"is_preprint":false},{"pmid":"24768767","id":"PMC_24768767","title":"GARNL1, a major RalGAP α subunit in skeletal muscle, regulates insulin-stimulated RalA activation and GLUT4 trafficking via interaction with 14-3-3 proteins.","date":"2014","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/24768767","citation_count":33,"is_preprint":false},{"pmid":"25220458","id":"PMC_25220458","title":"κB-Ras proteins regulate both NF-κB-dependent inflammation and Ral-dependent proliferation.","date":"2014","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/25220458","citation_count":33,"is_preprint":false},{"pmid":"15467745","id":"PMC_15467745","title":"The small G-protein RalA stimulates metastasis of transformed cells.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15467745","citation_count":33,"is_preprint":false},{"pmid":"28498728","id":"PMC_28498728","title":"A family affair: A Ral-exocyst-centered network links Ras, Rac, Rho signaling to control cell migration.","date":"2017","source":"Small GTPases","url":"https://pubmed.ncbi.nlm.nih.gov/28498728","citation_count":32,"is_preprint":false},{"pmid":"27510034","id":"PMC_27510034","title":"Phosphatidic Acid Produced by RalA-activated PLD2 Stimulates Caveolae-mediated Endocytosis and Trafficking in Endothelial Cells.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27510034","citation_count":31,"is_preprint":false},{"pmid":"23770673","id":"PMC_23770673","title":"The small GTPase RALA controls c-Jun N-terminal kinase-mediated FOXO activation by regulation of a JIP1 scaffold complex.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23770673","citation_count":31,"is_preprint":false},{"pmid":"32641778","id":"PMC_32641778","title":"κB-Ras and Ral GTPases regulate acinar to ductal metaplasia during pancreatic adenocarcinoma development and pancreatitis.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32641778","citation_count":30,"is_preprint":false},{"pmid":"22498113","id":"PMC_22498113","title":"Inhibition of RalA signaling pathway in treatment of non-small cell lung cancer.","date":"2012","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/22498113","citation_count":30,"is_preprint":false},{"pmid":"8769092","id":"PMC_8769092","title":"Association of Ral GTP-binding protein with human platelet dense granules.","date":"1996","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/8769092","citation_count":30,"is_preprint":false},{"pmid":"12135390","id":"PMC_12135390","title":"ADP-ribosylation and functional effects of Pseudomonas exoenzyme S on cellular RalA.","date":"2002","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12135390","citation_count":30,"is_preprint":false},{"pmid":"17462626","id":"PMC_17462626","title":"Functional analysis of RalGPS2, a murine guanine nucleotide exchange factor for RalA GTPase.","date":"2007","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/17462626","citation_count":30,"is_preprint":false},{"pmid":"30853556","id":"PMC_30853556","title":"RAL GTPases Drive Intestinal Stem Cell Function and Regeneration through Internalization of WNT Signalosomes.","date":"2019","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/30853556","citation_count":29,"is_preprint":false},{"pmid":"29899810","id":"PMC_29899810","title":"Gene therapy with RALA/iNOS composite nanoparticles significantly enhances survival in a model of metastatic prostate cancer.","date":"2018","source":"Cancer nanotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/29899810","citation_count":29,"is_preprint":false},{"pmid":"22790202","id":"PMC_22790202","title":"Differential involvement of RalA and RalB in colorectal cancer.","date":"2012","source":"Small GTPases","url":"https://pubmed.ncbi.nlm.nih.gov/22790202","citation_count":28,"is_preprint":false},{"pmid":"27178121","id":"PMC_27178121","title":"Two-Step Forward Genetic Screen in Mice Identifies Ral GTPase-Activating Proteins as Suppressors of Hepatocellular Carcinoma.","date":"2016","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/27178121","citation_count":28,"is_preprint":false},{"pmid":"34074494","id":"PMC_34074494","title":"The RAL signaling network: Cancer and beyond.","date":"2020","source":"International review of cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/34074494","citation_count":27,"is_preprint":false},{"pmid":"20679536","id":"PMC_20679536","title":"Ral isoforms are implicated in Fc gamma R-mediated phagocytosis: activation of phospholipase D by RalA.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20679536","citation_count":27,"is_preprint":false},{"pmid":"32993972","id":"PMC_32993972","title":"Collagen/GAG scaffolds activated by RALA-siMMP-9 complexes with potential for improved diabetic foot ulcer healing.","date":"2020","source":"Materials science & engineering. C, Materials for biological applications","url":"https://pubmed.ncbi.nlm.nih.gov/32993972","citation_count":26,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44612,"output_tokens":10003,"usd":0.14194},"stage2":{"model":"claude-opus-4-6","input_tokens":14029,"output_tokens":5010,"usd":0.293092},"total_usd":0.435032,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1986,\n      \"finding\": \"RALA was identified as a new RAS-related GTPase with GTP-binding domains and a C-terminal cysteine for membrane anchoring, predicting it to be a membrane-localized GTP-binding protein.\",\n      \"method\": \"cDNA cloning from simian B-lymphocyte library using synthetic oligonucleotide probe; sequence analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — foundational cloning and structural characterization, highly cited\",\n      \"pmids\": [\"3023062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Purified RalA protein binds and hydrolyzes GTP with low intrinsic GTPase activity (0.07 min-1 at 37°C) and slow GDP exchange; activating mutations (analogous to Ras Val12, Leu61) alter nucleotide exchange and GTPase activities, and NMR shows similar nucleotide-binding environment to p21Ras.\",\n      \"method\": \"In vitro biochemical assay with purified recombinant RalA; site-directed mutagenesis; NMR spectroscopy\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mutagenesis and NMR structural validation\",\n      \"pmids\": [\"2108160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"A cytosolic GTPase-activating protein (Ral-GAP) specific for RalA was identified in brain and testis; it stimulates RalA GTPase activity but not Ras, Rho, or Rap GTPase activity, demonstrating substrate specificity.\",\n      \"method\": \"Biochemical fractionation; in vitro GTPase activity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro assay with substrate specificity controls, single lab\",\n      \"pmids\": [\"1903395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"RalA interacts with phospholipase D (PLD); a Ral-specific N-terminal region is required for PLD association and PLD activation downstream of v-Src. Dominant-negative RalA inhibits v-Src- and v-Ras-induced PLD activity.\",\n      \"method\": \"Immunoprecipitation of PLD with immobilized RalA; dominant-negative overexpression; deletion mutagenesis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP and mutagenesis, published in Nature, highly cited\",\n      \"pmids\": [\"7477381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"RLIP76 (RalBP1) was identified as a RalA effector that binds activated (GTP-bound) RalA via its effector domain, and functions as a GAP for Rac1 and CDC42 but not RhoA, bridging Ral to Rho pathways.\",\n      \"method\": \"Yeast two-hybrid screening; biochemical pulldown with purified proteins; GAP activity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — yeast two-hybrid confirmed by in vitro pulldown and enzymatic activity assay, highly cited\",\n      \"pmids\": [\"7673236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Constitutively active RalA enhances Ras- and Raf-induced oncogenic transformation, while dominant-negative RalA suppresses transformation by RasH and Raf, placing Ral as a downstream effector in a Ras signaling pathway distinct from Raf.\",\n      \"method\": \"Genetic epistasis; dominant-negative and constitutively active mutant overexpression; transformation assay in mammalian cells\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis with gain- and loss-of-function mutants, highly cited\",\n      \"pmids\": [\"8631302\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Post-translational modification (prenylation) of both Ras and RalA is required for efficient RalGDS-mediated GDP/GTP exchange on RalA, for RalGDS membrane redistribution, and for RalA binding to its effector RalBP1.\",\n      \"method\": \"In vitro GDP/GTP exchange assay; cell fractionation; co-immunoprecipitation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple complementary biochemical methods, single lab\",\n      \"pmids\": [\"8702675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"RalA associates with an active PLD complex containing Arf proteins; the Ral-specific N-terminus is required for Arf association, and Arf is required for PLD activation in v-Src/v-Ras-transformed cells, demonstrating that RalA scaffolds a PLD-Arf complex.\",\n      \"method\": \"Pulldown with GST-RalA fusion; co-immunoprecipitation; Brefeldin A inhibitor study; dominant-negative Arf expression\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal pulldown, pharmacological and genetic perturbation, multiple orthogonal methods\",\n      \"pmids\": [\"9520417\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"RalA can be activated by a Ca2+-dependent, Ras-independent pathway triggered by LPA or EGF, involving phospholipase C activation; dominant-negative Ras did not block Ral-GTP loading.\",\n      \"method\": \"GTP-loading assay (Ral-GTP measurement) in Rat-2 fibroblasts; dominant-negative Ras; Ca2+ ionophore and PLC inhibitor\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological epistasis, single lab\",\n      \"pmids\": [\"9663394\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"GTP-bound RalA specifically binds filamin (an actin filament-crosslinking protein) and induces actin-rich filopodia; dominant-negative RalA or the RalA-binding domain of filamin blocks Cdc42-induced filopod formation. RalA does not generate filopodia in filamin-deficient cells, placing RalA downstream of Cdc42 in filopod production using filamin.\",\n      \"method\": \"GTP-specific binding assay; dominant-negative mutant expression; filamin-deficient cell rescue by transfection; fluorescence microscopy\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — GTP-specific binding, genetic epistasis, loss-of-function rescue, highly cited\",\n      \"pmids\": [\"10051605\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Positions 36 and 37 in the effector domain of RalA determine specificity of RalA-RLIP76 interaction; mutating these residues converts Ral/Ras effector interaction specificity, despite no sequence homology between their binding domains.\",\n      \"method\": \"Sequence analysis; site-directed mutagenesis; binding assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with binding validation, single lab\",\n      \"pmids\": [\"10364219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"RalA is required for v-Src- and v-Ras-induced urokinase-type plasminogen activator (uPA) and MMP-2/MMP-9 overproduction, and for tumor formation in mice; dominant-negative RalA blocks these effects.\",\n      \"method\": \"Dominant-negative RalA expression; zymogram for MMP activity; subcutaneous tumor injection in mice\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined cellular and in vivo phenotypes\",\n      \"pmids\": [\"10467419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"EGF activates c-Src through a RalA-dependent mechanism (but not beta2-adrenergic receptor signaling), leading to phosphorylation of Stat3 and cortactin but not Shc or Erk; RalA thus specifies c-Src substrate selectivity downstream of EGF receptor.\",\n      \"method\": \"Constitutively active RalA overexpression; dominant-negative mutants; phosphorylation assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function with phosphorylation readouts, single lab\",\n      \"pmids\": [\"10675331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"RalA and PLD1 cooperate with EGF receptor to transform 3Y1 rat fibroblasts; EGF-induced PLD activation requires both Ras and RalA, while Erk activation is RalA-independent. Overexpression of active RalA increases PLD activity and induces transformation.\",\n      \"method\": \"Dominant-negative RalA; PLD activity assay; transformation assay; co-immunoprecipitation\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss- and gain-of-function with enzymatic and phenotypic readouts\",\n      \"pmids\": [\"10611224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Dominant-negative RalA inhibits chemotactic migration of skeletal myoblasts in response to bFGF, HGF, and IGF-1; active Ral mutant or RalGDS stimulates motility; RalA-mediated motility requires binding to RalBP1 and PLD.\",\n      \"method\": \"Dominant-negative and constitutively active mutant overexpression; effector mutant analysis; chemotaxis assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — effector mutant epistasis with phenotypic readout\",\n      \"pmids\": [\"10848592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"RalA localizes to Weibel-Palade bodies in endothelial cells and is activated (GTP-loaded) by thrombin stimulation in a calmodulin-dependent manner; constitutively active RalA drives Weibel-Palade body exocytosis.\",\n      \"method\": \"Subcellular fractionation; GTP-loading assay; calmodulin inhibitor (trifluoperazine); dominant-active and dominant-negative RalA expression; immunofluorescence\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — localization linked to functional exocytosis, pharmacological and genetic perturbation\",\n      \"pmids\": [\"11397694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The mammalian exocyst subunit Sec5 is a specific binding partner for GTP-bound RalA; inhibition of RalA-Sec5 interaction prevents filopod formation by TNF-α, IL-1, and active RalA/Cdc42, linking RalA-exocyst interaction to cytoskeletal remodeling.\",\n      \"method\": \"Yeast two-hybrid; co-immunoprecipitation; dominant-negative interference; filopod assay\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP, GTP-specificity demonstrated, genetic interference with functional readout, highly cited\",\n      \"pmids\": [\"11744922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Pseudomonas ExoS ADP-ribosylates RalA at Arg52, inhibiting its ability to bind the RalBP1 effector; this identifies a post-translational modification that blocks RalA effector engagement.\",\n      \"method\": \"ADP-ribosylation assay; mass spectrometry for site identification; RalBP1-RBD binding assay in vitro and in cells\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic modification with site identification and functional binding assay\",\n      \"pmids\": [\"12135390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Beta-arrestins bind Ral-GDS and sequester it in an inactive cytosolic complex; upon fMLP receptor stimulation, beta-arrestin/Ral-GDS complexes dissociate, Ral-GDS translocates to plasma membrane, and activates RalA in a Ras-independent manner to drive cytoskeletal reorganization.\",\n      \"method\": \"Yeast two-hybrid; co-immunoprecipitation from PMNs; subcellular fractionation; Ral-GTP assay\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — yeast two-hybrid confirmed by co-IP from primary cells with functional readout\",\n      \"pmids\": [\"12105416\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Crystal structure of RalA-GppNHp bound to the Sec5 Ral-binding domain at 2.1 Å reveals Sec5 adopts an immunoglobulin-like beta-sandwich fold and contacts both switch regions of RalA; key residues Sec5-Thr11, Arg27 and RalA-Glu38 are required for complex formation.\",\n      \"method\": \"X-ray crystallography; isothermal titration calorimetry; mutagenesis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mutagenesis and ITC validation\",\n      \"pmids\": [\"12839989\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"RalBP1 interacts with HSF1 in a multiprotein complex with HSP90 and alpha-tubulin; constitutively active RalA enhances heat-inducible HSP70 expression while dominant-negative RalA suppresses it; upon heat shock, RalA-GTP binds RalBP1, releasing HSF1 for nuclear translocation.\",\n      \"method\": \"Yeast two-hybrid; co-immunoprecipitation; cotransfection with RalA mutants; reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — yeast two-hybrid plus co-IP with functional readout\",\n      \"pmids\": [\"12621024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"RalA interacts with ZONAB (a Y-box transcription factor) in a GTP-dependent manner; the RalA-ZONAB complex increases with epithelial cell density and relieves ZONAB-mediated transcriptional repression; oncogenic Ras alleviates ZONAB repression in a RalA-dependent manner.\",\n      \"method\": \"Reverse Ras recruitment system; co-immunoprecipitation; transcriptional reporter assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — novel interaction confirmed by co-IP with transcriptional functional readout\",\n      \"pmids\": [\"15592429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"RalA is associated with Weibel-Palade body dense granules in endothelial cells and is activated by cAMP-raising agents (epinephrine, forskolin) through a PKA-dependent mechanism; RalA activation is required for cAMP-mediated von Willebrand factor secretion.\",\n      \"method\": \"Cell-permeable peptide inhibition; PKA inhibitor (H-89); Ral-GTP loading assay; VWF secretion assay\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and peptide inhibition with functional secretion readout\",\n      \"pmids\": [\"15130921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Crystal structure of RalA bound to the Ral-binding domain (PH fold) of Exo84; Exo84 and Sec5 compete for the same binding site on active RalA via both switch regions; key interface residues were identified by mutagenesis.\",\n      \"method\": \"X-ray crystallography; mutagenesis; competitive binding assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mutagenesis and biochemical competition assay\",\n      \"pmids\": [\"15920473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"RalA but not RalB promotes neurite branching in neurons via the exocyst complex; RalB promotes branching via phospholipase D; Ral-dependent branching is mediated by PKC-dependent phosphorylation of GAP-43.\",\n      \"method\": \"Active Ral overexpression; RNAi knockdown; dominant-negative mutants; effector-binding mutants; neuronal morphology assay\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — isoform-selective RNAi and effector mutant epistasis with defined morphological readout\",\n      \"pmids\": [\"16330713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"RalA is required for tumor initiation in human pancreatic cancer cells (anchorage-independent growth and tumorigenesis), while RalB is required for invasion and metastasis; these are distinct and divergent functions of the two highly similar GTPases.\",\n      \"method\": \"siRNA knockdown of RalA vs RalB; anchorage-independent growth assay; invasion assay; tail-vein injection metastasis model\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic siRNA comparison across 10 cell lines with in vivo tumor and metastasis readouts\",\n      \"pmids\": [\"17174914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Insulin activates RalA in a PI 3-kinase-dependent manner in adipocytes; RalA is present in Glut4 vesicles and interacts with the exocyst complex to tether vesicles to the plasma membrane; RalA also interacts with Myo1c (a molecular motor), regulated by calmodulin, to function as a cargo receptor for Glut4 vesicle trafficking.\",\n      \"method\": \"RalA-GTP pulldown; siRNA knockdown; dominant-negative mutants; co-immunoprecipitation; glucose transport assay\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (pulldown, KD, co-IP, functional transport assay), single lab\",\n      \"pmids\": [\"17765682\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Activation of RalGEF/RalA pathway promotes prostate cancer metastasis specifically to bone; loss of RalA in PC3 cells inhibits bone metastasis but not subcutaneous tumor growth.\",\n      \"method\": \"RalA siRNA knockdown; in vivo bone metastasis assay; subcutaneous tumor growth comparison\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with in vivo metastasis readout\",\n      \"pmids\": [\"17709381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RalA is required for tethering the exocyst to the cytokinetic furrow in early cytokinesis; RalB is then required for exocyst recruitment to the midbody for abscission; each Ral isoform is controlled by distinct RalGEF proteins.\",\n      \"method\": \"RNAi knockdown; live cell imaging; immunofluorescence of cytokinesis stages\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — isoform-selective RNAi with defined spatial/temporal cytokinesis phenotypes\",\n      \"pmids\": [\"18756269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RalA (and RalB) control localization of the exocyst complex to focal complexes during cell migration by regulating interaction between Sec5 and paxillin; reduction of RalA or RalB by RNAi alters exocyst localization without disrupting steady-state exocyst assembly.\",\n      \"method\": \"RNAi knockdown; co-immunoprecipitation; immunofluorescence localization\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RNAi with co-IP and localization readout\",\n      \"pmids\": [\"18697830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Aurora-A kinase phosphorylates RalA at Ser194, promoting RalA activation and translocation from the plasma membrane; this phosphorylation activates RalBP1 effector and is required for Aurora-A-enhanced transformed cell growth.\",\n      \"method\": \"Kinase assay; phosphorylation site mutagenesis (S194); subcellular fractionation; transformation assay; tumor xenograft\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — kinase assay with mutagenesis, subcellular localization change, and in vivo tumorigenesis validation\",\n      \"pmids\": [\"19901077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"RalA mediates integrin-dependent membrane raft exocytosis via the exocyst complex; constitutively active RalA restores plasma membrane raft targeting to support anchorage-independent growth signaling.\",\n      \"method\": \"Dominant-active RalA; siRNA knockdown; membrane fractionation; growth signaling assay\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function with fractionation and growth readout\",\n      \"pmids\": [\"20005108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"M-Sec induces membrane nanotube formation by interacting with RalA and the exocyst complex; blockage of M-Sec interaction with Ral or the exocyst attenuates nanotube formation.\",\n      \"method\": \"RNAi knockdown; dominant-negative interference; live cell imaging of nanotubes\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and dominant-negative interference with live imaging readout\",\n      \"pmids\": [\"19935652\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"RalA and the exocyst complex associate with PAR-3 in a RalA-dependent manner during neuronal polarization; depletion of RalA or exocyst subunits inhibits axon formation, linking RalA-exocyst to PAR-3/aPKC polarity complex.\",\n      \"method\": \"Co-immunoprecipitation; RNAi knockdown; constitutively active RalA expression; neuronal morphology assay\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP with RNAi and functional polarity readout\",\n      \"pmids\": [\"19383721\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"A Ral GAP complex (RGC1/RGC2) is identified as the GAP that activates RalA downstream of PI 3-kinase/Akt; Akt2 phosphorylates RGC2, inhibiting its GAP activity and thereby activating RalA for GLUT4 vesicle targeting in adipocytes.\",\n      \"method\": \"RGC identification and characterization; in vitro GTPase assay; Akt2 phosphorylation assay; siRNA knockdown; glucose uptake assay\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro GAP assay with kinase phosphorylation and genetic validation\",\n      \"pmids\": [\"21148297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RalA is a positive modulator of FcγR-mediated phagocytosis through PLD activation; RalA colocalizes with PLD1 and PLD2 at the phagocytic cup, and RalA co-immunoprecipitates with PLD isoforms in a stimulation-dependent manner.\",\n      \"method\": \"RNAi knockdown; PLD activity assay; co-immunoprecipitation; fluorescence microscopy of phagocytic cup\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP plus localization linked to functional phagocytosis readout\",\n      \"pmids\": [\"20679536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"RalA null mice develop exencephaly and embryonic lethality; double Rala/Ralb null embryos do not survive past gastrulation; in a KRAS-driven lung cancer model, either RalA or RalB alone is sufficient for tumor growth, but loss of both blocks tumor formation.\",\n      \"method\": \"Genetic knockout mice; Kras-driven lung cancer model; conditional deletion\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic deletion with developmental and tumor phenotypes, replicated across multiple genetic backgrounds\",\n      \"pmids\": [\"23063435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"RALA is activated downstream of RalGAPα2 loss in bladder cancer; exogenous wild-type RalGAPα2 (but not a catalytically inactive mutant) reduces RalA activity, cell migration in vitro, and lung metastasis in vivo; Ralgapa2 knockout promotes tumor invasion in mice.\",\n      \"method\": \"RalGAPα2 expression rescue; in vitro migration assay; mouse tumor model; KO mouse\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — catalytic mutant rescue and in vivo validation\",\n      \"pmids\": [\"22450745\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ROS activates RalA via the exchange factor RLF, which is in complex with JIP1 scaffold and JNK; active RalA then promotes assembly and activation of MLK3-MKK4-JNK onto the JIP1 scaffold, leading to FOXO activation; this mechanism is conserved in C. elegans.\",\n      \"method\": \"Co-immunoprecipitation; RNAi knockdown; FOXO reporter/localization assay; C. elegans genetics\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP with genetic epistasis in two organisms\",\n      \"pmids\": [\"23770673\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Small molecules (RBC8, BQU57) bind the GDP-bound form of RalA/RalB, inhibit Ral-RALBP1 interaction, and inhibit Ral-mediated cell spreading and anchorage-independent growth; binding confirmed by ITC, SPR, and NMR spectroscopy.\",\n      \"method\": \"Structure-based virtual screening; ITC; SPR; TROSY NMR; cell spreading assay; xenograft tumor growth\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple biophysical methods confirming binding, functional cellular and in vivo validation\",\n      \"pmids\": [\"25219851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"In skeletal muscle, GARNL1/RalGAPα1 is a major RalGAP catalytic subunit; insulin activates RalA by Akt-mediated phosphorylation of GARNL1 at Thr735, causing 14-3-3 binding and GAP inactivation; knockdown of GARNL1 increases RalA activity and GLUT4 translocation.\",\n      \"method\": \"RalGAPα1 identification; phosphorylation site mutagenesis; 14-3-3 binding assay; siRNA knockdown; GLUT4 translocation assay\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — phosphorylation site identified with mutagenesis and functional GLUT4 translocation readout\",\n      \"pmids\": [\"24768767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Rab10 is activated by AS160 inactivation downstream of Akt; active Rab10 recruits the RalGEF Rlf/Rgl2 to GLUT4 vesicle membranes, activating RalA and thereby promoting maximal glucose transport; RalA is downstream of Rab10 in this cascade.\",\n      \"method\": \"GTP-loading assays; overexpression of membrane-tethered Rlf to bypass Rab10; siRNA knockdown; glucose transport assay\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis established by membrane-tethered rescue experiment\",\n      \"pmids\": [\"25103239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TD-60/RCC2 exhibits GEF activity for RalA in vitro and in cells; TD-60 and RalA depletion cause spindle abnormalities and abnormal CPC accumulation; several TD-60-depletion phenotypes are rescued by GTP-locked RalA(Q72L), placing RalA in the CPC regulatory pathway.\",\n      \"method\": \"In vitro GEF assay; RNAi knockdown; GTP-locked rescue; immunofluorescence of mitotic cells\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro GEF assay confirmed in cells with epistasis rescue\",\n      \"pmids\": [\"26158537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"RAL-1 (RalA ortholog in C. elegans) localizes to secretory multivesicular bodies (MVBs) and is required for both MVB biogenesis and fusion with the plasma membrane for exosome secretion; in mammalian cells, RalA and RalB are both required for exosome-like vesicle secretion.\",\n      \"method\": \"Live imaging; quantitative electron microscopy; RNAi knockdown in C. elegans; RalA/B knockdown in mammalian cells; nanoparticle tracking analysis\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — localization with quantitative EM phenotype and functional validation in two model systems\",\n      \"pmids\": [\"26459596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"RalA activates PLD2 in endothelial cells; phosphatidic acid produced by PLD2 facilitates caveolae-mediated endocytosis and vesicle trafficking; RalA co-immunoprecipitates with caveolin-1 and filamin A upon albumin stimulation.\",\n      \"method\": \"siRNA knockdown of RalA; PLD2 inhibition; co-immunoprecipitation; TIRF microscopy; PA biosensor\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP, biosensor, and functional endocytosis readout\",\n      \"pmids\": [\"27510034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"RALA and RALB are required for internalization of the Wnt receptor Frizzled-7 in intestinal stem cells; genetic deletion of either reduces ISC function and Lgr5 positivity, while dual deletion causes rapid crypt death.\",\n      \"method\": \"Genetic KO mouse; Drosophila genetics; Frizzled-7 internalization assay; intestinal organoid culture\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic deletion with receptor internalization mechanistic readout, conserved across species\",\n      \"pmids\": [\"30853556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"RalA and RalB control biogenesis and secretion of pro-metastatic extracellular vesicles through phospholipase D1; RalA/B-depleted cells produce EVs with elevated MCAM/CD146, reducing organotropic EV targeting and pre-metastatic niche formation.\",\n      \"method\": \"RalA/B knockdown; EV nanoparticle tracking; in vivo EV uptake assay; proteomics of EVs\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic RalA/B depletion with EV characterization and in vivo validation\",\n      \"pmids\": [\"33404012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"RalA expression and activity are increased in white adipocytes after high-fat diet; RalA drives mitochondrial fragmentation by reversing the inhibitory Ser637 phosphorylation of Drp1, increasing fission; adipocyte-specific RalA deletion prevents fragmentation, reduces weight gain, and increases fatty acid oxidation.\",\n      \"method\": \"Conditional adipocyte-specific RalA KO mouse; Drp1-Ser637 phosphorylation assay; mitochondrial morphology imaging; metabolic phenotyping\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — tissue-specific genetic KO with defined molecular mechanism (Drp1 dephosphorylation) and metabolic phenotype\",\n      \"pmids\": [\"38286821\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RALA is a membrane-localized small GTPase that cycles between GDP- and GTP-bound states under control of RalGEFs (activated by Ras, Rap1, Ca2+/calmodulin, or Rab10) and RalGAPs (inhibited by Akt-dependent phosphorylation); GTP-RalA engages multiple effectors including the exocyst complex (via Sec5 and Exo84) to drive vesicle trafficking, GLUT4 translocation, cytokinesis, and membrane nanotube formation, RLIP76/RalBP1 to regulate Rac/Cdc42 and stress signaling, phospholipase D1/D2 to generate phosphatidic acid for caveolae endocytosis and exosome biogenesis, filamin to induce filopodia downstream of Cdc42, and the JIP1 scaffold to activate JNK/FOXO; Aurora-A phosphorylates RalA at Ser194 to promote its plasma membrane-to-cytoplasm translocation and effector activation, while in obesity RalA promotes mitochondrial fission by reversing inhibitory Drp1-Ser637 phosphorylation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"RALA is a Ras-related small GTPase that functions as a central signaling hub linking growth factor, calcium, and Ras-dependent inputs to vesicle trafficking, cytoskeletal remodeling, and transcriptional regulation. Cycling between GDP- and GTP-bound states under the control of RalGEFs (activated by Ras, Ca²⁺/calmodulin, β-arrestin release, Rab10, and RCC2/TD-60) and RalGAP complexes (inhibited by Akt-mediated phosphorylation), GTP-loaded RalA engages a suite of effectors: the exocyst complex (via Sec5 and Exo84) to drive GLUT4 vesicle tethering, Weibel-Palade body exocytosis, cytokinesis, exosome secretion, Frizzled-7 internalization, and membrane nanotube formation; RLIP76/RalBP1 to regulate Rac/Cdc42 signaling, JNK-FOXO activation, and heat-shock responses; phospholipase D1/D2 to generate phosphatidic acid for caveolae endocytosis, phagocytosis, and extracellular vesicle biogenesis; and filamin to promote filopodia downstream of Cdc42 [PMID:7477381, PMID:7673236, PMID:11744922, PMID:15920473, PMID:10051605, PMID:17765682, PMID:26459596, PMID:30853556, PMID:18756269, PMID:23770673]. Aurora-A phosphorylates RalA at Ser194 to promote its translocation from the plasma membrane and enhance effector engagement during oncogenic growth [PMID:19901077]. RalA is essential for Ras-driven tumorigenesis and anchorage-independent growth in pancreatic and lung cancer models, RalA-null mice exhibit exencephaly and embryonic lethality, and in obesity RalA drives mitochondrial fission by reversing Drp1-Ser637 phosphorylation in adipocytes [PMID:25219851, PMID:23063435, PMID:38286821].\",\n  \"teleology\": [\n    {\n      \"year\": 1986,\n      \"claim\": \"The identity of RALA as a new Ras-related GTPase was established, revealing the existence of a distinct branch of the Ras superfamily with predicted membrane localization.\",\n      \"evidence\": \"cDNA cloning from simian B-lymphocyte library with sequence analysis identifying GTP-binding domains and C-terminal cysteine for prenylation\",\n      \"pmids\": [\"3023062\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No effectors or upstream regulators identified\", \"No functional role demonstrated\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Biochemical characterization showed RalA possesses low intrinsic GTPase activity and slow GDP exchange, and that activating mutations analogous to oncogenic Ras mutations alter these properties, establishing RalA as a bona fide GTP-hydrolyzing molecular switch.\",\n      \"evidence\": \"In vitro GTPase and exchange assays with purified recombinant RalA; site-directed mutagenesis; NMR spectroscopy\",\n      \"pmids\": [\"2108160\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No upstream activator (GEF) identified\", \"No downstream effectors known\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Discovery of a Ral-specific GAP in brain and testis demonstrated that RalA cycling is regulated by a dedicated GTPase-activating protein distinct from those acting on Ras, Rho, or Rap.\",\n      \"evidence\": \"Biochemical fractionation and in vitro GTPase assay with substrate specificity controls\",\n      \"pmids\": [\"1903395\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular identity of the GAP not determined\", \"Single biochemical fractionation without molecular cloning\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identification of the first RalA effectors—phospholipase D and RLIP76/RalBP1—revealed that RalA connects to lipid signaling (PLD) and Rho-family GTPase regulation (via RLIP76's GAP activity toward Rac1/Cdc42), establishing two major downstream branches.\",\n      \"evidence\": \"Immunoprecipitation of PLD with RalA, deletion mutagenesis (PLD); yeast two-hybrid and in vitro pulldown with GAP activity assay (RLIP76)\",\n      \"pmids\": [\"7477381\", \"7673236\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological contexts for PLD and RLIP76 signaling undefined\", \"No structural detail on effector contacts\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Epistasis experiments with constitutively active and dominant-negative RalA showed that Ral operates as a Ras effector pathway distinct from Raf, contributing to oncogenic transformation, and that prenylation of both Ras and RalA is required for efficient signal relay through RalGDS.\",\n      \"evidence\": \"Gain- and loss-of-function mutant overexpression in transformation assays; GDP/GTP exchange assays requiring prenylation\",\n      \"pmids\": [\"8631302\", \"8702675\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity and diversity of RalGEF proteins incompletely mapped\", \"Whether Ral operates independently of Ras not resolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Two Ras-independent activation modes for RalA were uncovered: Ca²⁺/PLC-dependent activation by LPA/EGF, and RalA scaffolding of an Arf–PLD complex, broadening the upstream inputs and mechanistic outputs of the pathway.\",\n      \"evidence\": \"Ral-GTP loading assays with dominant-negative Ras, Ca²⁺ ionophore, PLC inhibitor; GST-RalA pulldown identifying Arf co-association; Brefeldin A and dominant-negative Arf perturbation\",\n      \"pmids\": [\"9663394\", \"9520417\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific RalGEF linking Ca²⁺ to RalA not identified\", \"Stoichiometry of the Ral-Arf-PLD complex undefined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"RalA was placed downstream of Cdc42 in filopodium formation through direct GTP-dependent binding to filamin, and was shown to contribute to Ras-driven tumor invasion by controlling uPA and MMP expression.\",\n      \"evidence\": \"GTP-specific binding assay and filamin-deficient cell rescue; dominant-negative RalA blocking MMP overproduction and in vivo tumorigenesis\",\n      \"pmids\": [\"10051605\", \"10467419\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Cdc42 activates RalA mechanistically not established\", \"Filamin interaction structure unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"The exocyst subunit Sec5 was identified as a direct GTP-dependent effector of RalA, and β-arrestin was shown to sequester RalGDS until receptor stimulation, revealing a new effector arm (exocyst) and a Ras-independent activation mechanism (β-arrestin/GPCR).\",\n      \"evidence\": \"Yeast two-hybrid and co-immunoprecipitation confirming GTP-specific Sec5 binding with filopod functional readout; co-IP of β-arrestin/RalGDS from primary PMNs with Ral-GTP assay\",\n      \"pmids\": [\"11744922\", \"12105416\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of RalA–Sec5 not yet determined at this time\", \"Full set of exocyst subunits engaging RalA unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"The crystal structure of the RalA·GppNHp–Sec5 complex at 2.1 Å revealed that Sec5 adopts an immunoglobulin-like fold contacting both switch regions of RalA, providing the first atomic-resolution view of how RalA recruits the exocyst.\",\n      \"evidence\": \"X-ray crystallography with ITC and mutagenesis validation\",\n      \"pmids\": [\"12839989\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of RalA with other effectors not yet solved\", \"Mechanism of exocyst complex assembly upon RalA binding unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Crystal structure of RalA bound to Exo84's PH-fold Ral-binding domain showed that Sec5 and Exo84 compete for the same switch-region surface on RalA, establishing that RalA engages two distinct exocyst subunits in a mutually exclusive manner to potentially coordinate sequential trafficking steps.\",\n      \"evidence\": \"X-ray crystallography; competitive binding assay; mutagenesis\",\n      \"pmids\": [\"15920473\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of Sec5 vs Exo84 engagement in specific trafficking events unclear\", \"Full exocyst reconstitution with RalA not performed\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"RalA was established as a critical node in insulin-stimulated GLUT4 vesicle exocytosis: insulin activates RalA via PI3K, and RalA then bridges GLUT4 vesicles to the exocyst and the motor protein Myo1c for plasma membrane tethering.\",\n      \"evidence\": \"Ral-GTP pulldown, siRNA knockdown, co-IP with Myo1c, dominant-negative mutants, glucose transport assay in adipocytes\",\n      \"pmids\": [\"17765682\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How RalA coordinates with Rab proteins on the same vesicle not resolved\", \"Precise step at which RalA acts (tethering vs fusion) ambiguous\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Systematic comparison in pancreatic cancer cells revealed that RalA is selectively required for anchorage-independent growth and tumor initiation, while RalB drives invasion and metastasis, demonstrating functional divergence despite >80% sequence identity.\",\n      \"evidence\": \"siRNA knockdown of RalA vs RalB across 10 cell lines; anchorage-independent growth; tail-vein metastasis model\",\n      \"pmids\": [\"17174914\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of isoform-specific effector engagement unclear\", \"Whether isoform divergence is tissue-dependent not fully tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"RalA was shown to tether the exocyst to the cytokinetic furrow during early cytokinesis and to regulate exocyst targeting to focal complexes during cell migration via Sec5–paxillin interaction, extending RalA-exocyst function to cell division and motility.\",\n      \"evidence\": \"RNAi knockdown with live cell imaging of cytokinesis stages; co-IP of exocyst-paxillin with RalA depletion\",\n      \"pmids\": [\"18756269\", \"18697830\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"RalGEF identity at the furrow not determined\", \"Whether RalA and RalB have sequential roles confirmed only partially\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Aurora-A was identified as a kinase that phosphorylates RalA at Ser194, promoting RalA translocation from the plasma membrane and activating RalBP1-dependent effector signaling required for transformation—revealing a mitotic kinase input to Ral signaling.\",\n      \"evidence\": \"In vitro kinase assay; S194 mutagenesis; subcellular fractionation; tumor xenograft\",\n      \"pmids\": [\"19901077\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphatase opposing Aurora-A at Ser194 unknown\", \"Whether Ser194 phosphorylation affects exocyst or PLD arms not tested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"The molecular identity of the RalGAP complex (RGC1/RGC2) was established, and Akt2-mediated phosphorylation of RGC2 was shown to inhibit GAP activity, providing the mechanistic link between insulin/PI3K/Akt signaling and RalA activation for GLUT4 translocation.\",\n      \"evidence\": \"In vitro GAP assay; Akt2 phosphorylation site identification; siRNA knockdown; glucose uptake assay\",\n      \"pmids\": [\"21148297\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other kinases regulate RGC under different stimuli unclear\", \"Structural basis of RGC catalysis unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"A ROS-responsive pathway was delineated in which the RalGEF RLF activates RalA on a JIP1 scaffold, promoting assembly of a MLK3-MKK4-JNK cascade and FOXO activation—a mechanism conserved in C. elegans—linking RalA to oxidative stress and longevity signaling.\",\n      \"evidence\": \"Co-immunoprecipitation; RNAi knockdown; FOXO reporter assay; C. elegans epistasis\",\n      \"pmids\": [\"23770673\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding between RalA and JIP1 not demonstrated in vitro\", \"Physiological ROS levels required for this pathway not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Small-molecule inhibitors (RBC8, BQU57) that bind GDP-bound RalA and block effector engagement were developed and validated biophysically and in vivo, providing first chemical tools to pharmacologically target the Ral pathway.\",\n      \"evidence\": \"Virtual screening; ITC, SPR, TROSY-NMR binding confirmation; cell spreading and xenograft tumor growth inhibition\",\n      \"pmids\": [\"25219851\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Selectivity over RalB not fully characterized\", \"In vivo pharmacokinetics and therapeutic window undefined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"RalA was placed in the chromosomal passenger complex (CPC) regulatory pathway through TD-60/RCC2 acting as a RalA GEF during mitosis, and in exosome biogenesis through localization to multivesicular bodies and requirement for MVB fusion with the plasma membrane.\",\n      \"evidence\": \"In vitro GEF assay with RCC2; RNAi and GTP-locked rescue of spindle phenotypes; EM and live imaging of MVBs in C. elegans; nanoparticle tracking in mammalian cells\",\n      \"pmids\": [\"26158537\", \"26459596\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether RalA directly associates with CPC components unknown\", \"Step at which RalA acts in MVB biogenesis vs fusion not distinguished cleanly\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"In vivo genetic deletion in intestinal epithelium showed that RalA (and RalB) are required for Frizzled-7 internalization and intestinal stem cell maintenance, positioning Ral GTPases as essential regulators of Wnt receptor endocytosis in tissue homeostasis.\",\n      \"evidence\": \"Conditional KO mouse; Drosophila genetics; Frizzled-7 internalization assay; organoid culture\",\n      \"pmids\": [\"30853556\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Effector pathway mediating Frizzled-7 internalization (exocyst vs PLD) not resolved\", \"Whether RalA acts at internalization or recycling step unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"In obesity, RalA activity increases in white adipocytes and drives mitochondrial fragmentation by reversing inhibitory Drp1-Ser637 phosphorylation, identifying a previously unrecognized metabolic role for RalA in controlling mitochondrial dynamics.\",\n      \"evidence\": \"Adipocyte-specific conditional RalA KO mouse; Drp1-Ser637 phosphorylation assay; mitochondrial imaging; metabolic phenotyping\",\n      \"pmids\": [\"38286821\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphatase recruited by RalA to dephosphorylate Drp1-Ser637 not identified\", \"Whether this mechanism operates in other metabolically active tissues unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis of RalA selectivity for specific effectors versus RalB, the identity of phosphatases that reverse Aurora-A and Akt regulatory inputs, how competing effector interactions (Sec5 vs Exo84 vs RLIP76 vs PLD) are spatiotemporally resolved within a single cell, and whether the metabolic (Drp1) function is a direct or indirect consequence of RalA effector engagement.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structure of full exocyst with RalA\", \"No phosphatase for Ser194 identified\", \"Isoform-specific effector selection mechanism unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003924\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 4, 26, 47]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 6, 26, 30]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [15, 22, 26, 43]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [30]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 5, 8, 18, 38]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [15, 16, 26, 43, 44, 45]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [28, 42]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 25, 27, 36, 37]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [26, 34, 40, 47]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [26, 40, 41]}\n    ],\n    \"complexes\": [\n      \"Exocyst complex\"\n    ],\n    \"partners\": [\n      \"SEC5\",\n      \"EXO84\",\n      \"RLIP76\",\n      \"PLD1\",\n      \"PLD2\",\n      \"FLNA\",\n      \"RALGDS\",\n      \"MYO1C\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}